Asthma and COPD Drugs Industry - Regional Synopsis
North America Market Analysis
North America is predicted to capture the highest share of 34.3% in the global asthma and COPD drugs market over the assessed period. The enlarging patient pool, provincial government spending, and strong reimbursement structure are accumulatively consolidating the region's leadership. Testifying this, the WHO reported that more than 40.2 million incidences of asthma were recorded across North America in 2024. Furthermore, the well-polished domestic and international operations of local manufacturers maintain the region's control over the global trade in this category. As evidence, in 2023, the International Trade Commission (ITC) highlighted the dominance of the U.S., besides Europe, on global exports of respiratory drugs (65.2%).
The U.S. is dominating the regional asthma and COPD drugs market by holding a large proportion of the patient pool and biologics innovations. Additionally, the presence of a strong Medicare & Medicaid infrastructure and a favorable regulatory framework is also fueling the country's predominant augmentation. One of these growth factors is further displayed in the calculated population of asthma and COPD patients, which crossed 25.2 million and 16.1 million, respectively, according to the CDC. Alongside, the expansion in Part D coverage by Medicare enlisted 80.3% of COPD medicines, showcasing a 60.3% rise from 2020 to 2024. This creates a favorable atmosphere for securing greater profit margins.
Canada is also following the region's pathway of growth in the asthma and COPD drugs market with a universal healthcare-driven approach. This, coupled with the amplifying government investments in elder care, is propelling the country's progress in this sector. For instance, from 2021 to 2024, the 18.2% expenditure increase helped the governing bodies of Ontario avail treatments to an additional 200,010 residents. Additionally, the frequent prevalence of wildfires is raising the volume of the patient pool, driving the count of COPD cases by 12.2% in 2023. Furthermore, similar to the U.S., Canada is also focusing on broadening patient access to related products, such as inhalers.
APAC Market Statistics
Asia Pacific is projected to propagate the asthma and COPD drugs market with the highest CAGR by 2037. Rapid urbanization, aging, and sedentary lifestyle adoption are the key growth drivers in the associated patient pool. Particularly, in emerging economies, such as India and China, air pollution is becoming an international environmental issue, which is propelling the number of afflictions. In addition, the gap in accessibility creates new business opportunities for both domestic and foreign companies, attracting them to participate. For instance, in Japan, the count of citizens with uncontrolled asthma crossed 3.3 million, and 40.2% of this demography faces disparity in accessing expensive biologics, which embarks the growing demand for affordable biosimilars.
China is augmenting leadership over the APAC asthma and COPD drugs market with its predominant captivity in API production, supply, and explorations. In addition, the country is home to the largest consumer base and payers, where the number of asthma and COPD patients surpassed 45.8 million and 58.2 million in 2024. This is dragging the focus of national healthcare associations for investing in respiratory medications. Testifying this, the National Health Commission in China, calculated the yearly government expenditure on the same category, from 2019 to 2024, to be USD 5.2 billion and exhibit a 15.2% rise. Furthermore, the nation's ambitious goal of achieving a forefront position in producing maximum biologics is empowering its regional dominance.
According to a report from the WHO, the volume of asthma and COPD patients in India reached 32.5 million and 29.0 million in 2024. This demonstrates a sustainable demand and reliable consumer base for this merchandise. Moreover, the steady capital influx from governing bodies and foreign investors to improve the nation's healthcare system and accessibility is procuring a progressive environment for the asthma and COPD drugs market. As evidence, in 2023 alone, the government spending on healthcare totaled USD 1.9 billion, reflecting an 18.2% rise from 2018.
